• Limited effect on short-term earnings, higher perceived risk
• Bioextrax signs MoU with Chematur Engineering
• We have adjusted the fair value to SEK 7.60 (10.50) per share

In September 2023, an American start-up company extended the license agreement with Bioextrax regarding production of PHA. In January 2024, the American company had to terminate the contract due to financial issues. Hence, our model suggests a fair value of SEK 7.60 per share.

The initial research report is available here.

About Market Focus

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Finance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se (https://twitter.com/vhcorp_se)